Specialty biopharmaceutical company EyePoint Pharmaceuticals signed an agreement with the Department of Veteran Affairs to add two of its products to the federal supply schedule.
Through the agreement, EyePoint's Yutiq and Dexycu products for eye surgery will be available to 9 million VA beneficiaries and federal employees. The contract will last five years.
“This new agreement with the VA further extends the commercial reach of Dexycu and Yutiq to patients suffering from ocular diseases in areas of high unmet medical need,” said Nancy Lurker, president and CEO of Watertown-Mass.-based EyePoint Pharmaceuticals.